28 May 2015
The new drug combination showed an advantage in three of a total of 16 patient groups, particularly regarding virologic response. The extent of added benefit remains unclear, however.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/rneVPQ6mqvU/150528104114.htm
